Catabasis, Now Renamed Astria, Working Toward HAE Trial Launch

Catabasis, Now Renamed Astria, Working Toward HAE Trial Launch

307426

Catabasis, Now Renamed Astria, Working Toward HAE Trial Launch

Astria Therapeutics is the new name of the company that’s developing STAR-0215, an investigational kallikrein-inhibitor previously known as QLS-215, for the treatment of hereditary angioedema (HAE). Formerly called Catabasis Pharmaceuticals, the company said it changed its name to reflect its pledge of having patients serve as its guiding stars. According to the company, Astria “originates from the Greek word for star.” Earlier this year, STAR-0215 became Astria’s lead product following the acquisition of Quellis Biosciences,…

You must be logged in to read/download the full post.